Table 5.
Association between CHIM and past duration of NSAID use in 39 chronic NSAID users
| CIHM (n) | Past duration of NSAIDs(Mean ± SD): years | Multivariate analysis | |
|---|---|---|---|
| OR (95% CI) | P‐values | ||
| p14 | |||
| UM (34) | 1.46 ± 1.04 | Reference | |
| M (5) | 3.09 ± 3.36 | 1.68 (0.77–3.66) | 0.20 |
| p16 | |||
| UM (34) | 1.49 ± 0.91 | Reference | |
| M (5) | 2.88 ± 3.77 | 1.46 (0.83–2.58) | 0.19 |
| DAP‐kinase | |||
| UM (27) | 1.51 ± 0.91 | Reference | |
| M (12) | 2.03 ± 2.49 | 1.22 (0.76–1.95) | 0.41 |
| CDH1 | |||
| UM (35) | 1.49 ± 1.01 | Reference | |
| M (4) | 3.28 ± 3.92 | 1.65 (0.84–3.25) | 0.14 |
| CIHM high | |||
| (–) (33) | 1.42 ± 0.93 | Reference | |
| (+) (6) | 3.17 ± 3.19 | 1.72 (0.88–3.38) | 0.12 |
Note: All data were adjusted for age, sex, and Helicobacter pylori infection status. CIHM high was defined as two or more CpG islands methylated.
CDH1, E‐cadherin; CI, confidence interval; CIHM, CpG island hyper methylation; DAP‐kinase, death‐associated protein kinase; M, methylated; NSAID, nonsteroidal anti‐inflammatory drug; OR, odds ratio; UM, unmethylated.